Published in Bioorg Med Chem on June 02, 2008
Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine. PET Clin (2009) 0.82
Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters. Bioorg Med Chem (2009) 0.75
Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science (1987) 6.58
Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci (1998) 3.16
The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci (1991) 3.07
Summary of the 2009 National Survey on Drug Use and Health. J Pain Palliat Care Pharmacother (2010) 2.95
Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature (1997) 2.94
Fluctuations in nucleus accumbens dopamine concentration during intravenous cocaine self-administration in rats. Psychopharmacology (Berl) (1995) 2.60
Chemistry, design, and structure-activity relationship of cocaine antagonists. Chem Rev (2000) 2.46
Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther (1989) 2.04
On the relationship between the dopamine transporter and the reinforcing effects of local anesthetics in rhesus monkeys: practical and theoretical concerns. Psychopharmacology (Berl) (2000) 1.28
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy. J Med Chem (2003) 1.27
Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic--A focus on analogues of benztropine and rimcazole. Med Res Rev (2002) 1.17
Dopamine transporter ligands: recent developments and therapeutic potential. Curr Top Med Chem (2006) 1.15
Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3beta-(substituted phenyl)-2beta-(3'-substituted isoxazol-5-yl)tropanes. J Med Chem (2004) 1.12
Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. AAPS J (2006) 1.12
Dopamine transporter as target for drug development of cocaine dependence medications. Eur J Pharmacol (2003) 1.07
Compounds affecting the central nervous system. 4. 3 Beta-phenyltropane-2-carboxylic esters and analogs. J Med Chem (1973) 1.05
Synthesis, ligand binding, QSAR, and CoMFA study of 3 beta-(p-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters. J Med Chem (1991) 1.02
Cocaine pharmacology and current pharmacotherapies for its abuse. Bioorg Med Chem (2004) 1.02
Cocaine receptor: biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J Med Chem (1992) 1.00
Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration. Eur J Pharmacol (2006) 0.99
Cocaine use and high-risk sexual behavior among STD clinic patients. Sex Transm Dis (1999) 0.95
Synthesis of 2 beta-acyl-3 beta-aryl-8-azabicyclo[3.2.1]octanes and their binding affinities at dopamine and serotonin transport sites in rat striatum and frontal cortex. J Med Chem (1994) 0.94
3-Aryl-2-(3'-substituted-1',2',4'-oxadiazol-5'-yl)tropane analogues of cocaine: affinities at the cocaine binding site at the dopamine, serotonin, and norepinephrine transporters. J Med Chem (1993) 0.93
Isothiocyanate derivatives of cocaine: irreversible inhibition of ligand binding at the dopamine transporter. Mol Pharmacol (1991) 0.85
Synthesis, dopamine transporter affinity, dopamine uptake inhibition, and locomotor stimulant activity of 2-substituted 3 beta-phenyltropane derivatives. J Med Chem (1997) 0.83
Synthesis and ligand binding study of 3 beta-(4'-substituted phenyl)-2 beta-(heterocyclic)tropanes. J Med Chem (1995) 0.82
Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes. J Med Chem (2007) 0.78
Structure of the human κ-opioid receptor in complex with JDTic. Nature (2012) 5.18
Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol (2006) 3.84
Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl) (2005) 2.60
Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther (2007) 2.06
Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol (2004) 1.88
New colchicinoids from a native Jordanian meadow saffron, colchicum brachyphyllum: isolation of the first naturally occurring dextrorotatory colchicinoid. J Nat Prod (2005) 1.59
Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci (2003) 1.59
Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther (2007) 1.57
Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol (2003) 1.49
PETS and postmarketing surveillance of veterinary rabies vaccines authorised in the UK. Vet Rec (2003) 1.40
Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther (2006) 1.34
Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry (2011) 1.33
Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacol Biochem Behav (2008) 1.31
Concurrent autoreceptor-mediated control of dopamine release and uptake during neurotransmission: an in vivo voltammetric study. J Neurosci (2002) 1.31
Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. Vaccine (2009) 1.31
Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol (2009) 1.28
Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. Pharmacol Biochem Behav (2006) 1.28
Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging. J Pharmacol Exp Ther (2004) 1.24
Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem (2009) 1.22
Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol Pharmacol (2011) 1.20
Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats. J Pain (2013) 1.18
Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol Biochem Behav (2008) 1.17
Dopamine transporter ligands: recent developments and therapeutic potential. Curr Top Med Chem (2006) 1.15
Bupropion increases striatal vesicular monoamine transport. Neuropharmacology (2005) 1.14
Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2'-fluoro-3'-(substituted phenyl)deschloroepibatidine analogues. Novel nicotinic antagonist. J Med Chem (2004) 1.09
Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats. Psychopharmacology (Berl) (2010) 1.06
Discovery of an opioid kappa receptor selective pure antagonist from a library of N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphans. J Med Chem (2002) 1.06
Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2',3'-disubstituted 5'-pyridinyl)-7-azabicyclo[2.2.1]heptanes: epibatidine analogues. J Med Chem (2002) 1.05
2-Fluoro-3-(4-nitro-phenyl)deschloroepibatidine is a novel potent competitive antagonist of human neuronal alpha4beta2 nAChRs. Mol Pharmacol (2006) 1.04
Importance of phenolic address groups in opioid kappa receptor selective antagonists. J Med Chem (2004) 1.03
The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety. Addict Biol (2012) 1.03
Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration. Psychopharmacology (Berl) (2010) 1.02
Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem (2010) 1.02
Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3'-substituted deschloroepibatidine analogues. Novel nicotinic antagonists. J Med Chem (2005) 1.01
Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem (2010) 1.01
Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys. Pharmacol Biochem Behav (2005) 1.00
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology (Berl) (2010) 1.00
A reduced rate of in vivo dopamine transporter binding is associated with lower relative reinforcing efficacy of stimulants. Neuropsychopharmacology (2006) 0.99
Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice. J Pharmacol Exp Ther (2010) 0.99
Structure-activity correlations for beta-phenethylamines at human trace amine receptor 1. Bioorg Med Chem (2008) 0.99
Synthesis, nicotinic acetylcholine receptor binding, antinociceptive and seizure properties of methyllycaconitine analogs. Bioorg Med Chem (2006) 0.98
Orphanin FQ/nociceptin blocks cocaine-induced behavioral sensitization in rats. Psychopharmacology (Berl) (2002) 0.97
The antinociceptive effects of nicotinic receptors α7-positive allosteric modulators in murine acute and tonic pain models. J Pharmacol Exp Ther (2012) 0.95
Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. BMC Pharmacol (2012) 0.95
Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food. Vaccine (2013) 0.95
Self-administration of drug mixtures by monkeys: combining drugs with comparable mechanisms of action. Psychopharmacology (Berl) (2007) 0.95
Synthesis, nicotinic acetylcholine receptor binding, and pharmacological properties of 3'-(substituted phenyl)deschloroepibatidine analogs. Bioorg Med Chem (2007) 0.95
A semantic sensor web for environmental decision support applications. Sensors (Basel) (2011) 0.94
Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the κ-opioid receptor antagonist JDTic. Neuropsychopharmacology (2012) 0.93
N-substituted 4beta-methyl-5-(3-hydroxyphenyl)-7alpha-amidomorphans are potent, selective kappa opioid receptor antagonists. J Med Chem (2006) 0.93
The long-lasting effects of JDTic, a kappa opioid receptor antagonist, on the expression of ethanol-seeking behavior and the relapse drinking of female alcohol-preferring (P) rats. Pharmacol Biochem Behav (2012) 0.92
Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition. J Pharmacol Exp Ther (2008) 0.92
[125I]Iodomethyllycaconitine binds to alpha7 nicotinic acetylcholine receptors in monkey brain. Eur J Neurosci (2006) 0.92
Synthesis and pharmacological characterization of exo-2-(2'-chloro-5-pyridinyl)-7-(endo and exo)-aminobicyclo[2.2.1]heptanes as novel epibatidine analogues. J Med Chem (2005) 0.91
Novel bioactive clerodane diterpenoids from the leaves and twigs of Casearia sylvestris. J Nat Prod (2002) 0.91
Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes. J Med Chem (2005) 0.91
Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats. J Psychiatry Neurosci (2004) 0.91
N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists. J Med Chem (2005) 0.90
Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3'-(substituted phenyl)epibatidine analogues. Nicotinic partial agonists. J Nat Prod (2010) 0.89
Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. Psychopharmacology (Berl) (2010) 0.88
Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: possible confounding effects on in vivo and in vitro studies. Bioorg Med Chem Lett (2012) 0.88
Synthesis and pharmacological evaluation of phenylethynyl[1,2,4]methyltriazines as analogues of 3-methyl-6-(phenylethynyl)pyridine. J Med Chem (2007) 0.87
Effects of ketoprofen, morphine, and kappa opioids on pain-related depression of nesting in mice. Pain (2015) 0.87
Lower reinforcing strength of the phenyltropane cocaine analogs RTI-336 and RTI-177 compared to cocaine in nonhuman primates. Pharmacol Biochem Behav (2010) 0.87
A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay. Bioorg Med Chem (2007) 0.87
Modification of the gold-weight implant for insertion into the upper eyelid in facial palsy. Ann Plast Surg (2005) 0.87
New aporphinoid 5-HT2A and α1A antagonists via structural manipulations of nantenine. Bioorg Med Chem (2011) 0.87
Identifying structural features on 1,1-diphenyl-hexahydro-oxazolo[3,4-a]pyrazin-3-ones critical for Neuropeptide S antagonist activity. Bioorg Med Chem Lett (2008) 0.87
Withdrawal from repeated cocaine alters dopamine transporter protein turnover in the rat striatum. J Pharmacol Exp Ther (2003) 0.87
Influence of chronic dopamine transporter inhibition by RTI-336 on motor behavior, sleep, and hormone levels in rhesus monkeys. Exp Clin Psychopharmacol (2011) 0.86
The antinociceptive effects of nicotinic partial agonists varenicline and sazetidine-A in murine acute and tonic pain models. J Pharmacol Exp Ther (2012) 0.86
Cocaine self-administration and locomotor activity are altered in Lewis and F344 inbred rats by RTI 336, a 3-phenyltropane analog that binds to the dopamine transporter. Brain Res (2005) 0.86
Effects of pyridine ring substitutions on affinity, efficacy, and subtype selectivity of neuronal nicotinic receptor agonist epibatidine. J Pharmacol Exp Ther (2002) 0.86
Discriminative stimulus and hypothermic effects of some derivatives of the nAChR agonist epibatidine in mice. Psychopharmacology (Berl) (2014) 0.84
Studies of the biogenic amine transporters. VIII: identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding. Synapse (2002) 0.84
Patterns of nicotinic receptor antagonism II: cardiovascular effects in rats. Drug Alcohol Depend (2013) 0.84
Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter. J Med Chem (2008) 0.83
Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease. J Pharmacol Exp Ther (2013) 0.83
Chronic cocaine increases kappa-opioid receptor density: lack of effect by selective dopamine uptake inhibitors. Synapse (2002) 0.83
RTI 113, a 3-phenyltropane analog, produces long-lasting cocaine-like discriminative stimulus effects in rats and squirrel monkeys. Eur J Pharmacol (2002) 0.83
Effects of acute and chronic social defeat stress are differentially mediated by the dynorphin/kappa-opioid receptor system. Behav Pharmacol (2015) 0.81
Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2-methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists. J Med Chem (2013) 0.81
Nicotinic acetylcholine receptor efficacy and pharmacological properties of 3-(substituted phenyl)-2β-substituted tropanes. J Med Chem (2010) 0.81
Discovery of the first N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphan to possess highly potent and selective opioid delta receptor antagonist activity. J Med Chem (2004) 0.81